Results 231 to 240 of about 53,302 (297)
Some of the next articles are maybe not open access.

Clinical use of non-a botulinum toxins: Botulinum toxin type C and botulinum toxin type F

Neurotoxicity Research, 2006
Botulinum neurotoxin (BoNT) serotype A is commonly used in the treatment of focal dystonia, but some patients are primarily or become secondarily resistant to it. Consequently, other serotypes have to be used when immuno-resistance is proven. In the literature, patients with focal dystonia have been treated with BoNT serotype F with clinical benefit ...
ELEOPRA R   +5 more
openaire   +3 more sources

Complications of Botulinum Toxin Type A

Facial Plastic Surgery Clinics of North America, 2007
Introduced over 30 years ago for the treatment of strabismus and blepharospasm, botulinum toxin type A (BTX-A) now has established uses for various therapeutic and cosmetic purposes. Although remarkably safe and effective, BTX-A is a potent toxin. Complications can occur, particularly when used by the inexperienced injectors.
Jean, Carruthers, Alastair, Carruthers
openaire   +2 more sources

What Are the Most Commonly Reported Complications With Cosmetic Botulinum Toxin Type A Treatments?

Journal of oral and maxillofacial surgery, 2020
PURPOSE The purpose of the present study was to determine the most commonly reported complications with cosmetic botulinum toxin type A (BTX-A) treatments.
Kevin C. Lee   +3 more
semanticscholar   +1 more source

Neurophysiological effects of botulinum toxin type a

Neurotoxicity Research, 2006
Botulinum toxin type A (BoNT-A) acts peripherally by inhibiting acetylcholine release from the presynaptic neuromuscular terminals, thus weakening muscle contraction, and its clinical benefit depends primarily on the toxin's peripheral action. In addition to acting directly at the neuromuscular junction, the toxin alters sensory inputs to the central ...
ABBRUZZESE, GIOVANNI, BERARDELLI A.
openaire   +3 more sources

Clinical outcomes of botulinum toxin type A injections in the management of primary bruxism in adults: A systematic review.

The Journal of prosthetic dentistry (Print), 2020
STATEMENT OF PROBLEM Botulinum toxin has been used for various therapeutic and esthetic purposes for nearly 4 decades and has shown positive outcomes in patients with bruxism.
L. Sendra   +3 more
semanticscholar   +1 more source

Botulinum toxin in tension-type headache

Journal of Neurology, 2004
Despite the controversy regarding specific mechanism of botulinum toxin action in pain relief, clinical results suggest that botulinum toxin type A may be promising treatment options for patients with primary chronic headache. To investigate this, we included sixteen patients with chronic tension-type headache in a prospective double blind, placebo ...
Telarović, Srđana, Relja, Maja
openaire   +6 more sources

Clinical use of non-a botulinum toxins: botulinum toxin type B

Neurotoxicity Research, 2006
Botulinum neurotoxin type B (BT, BT-B) has been used as NeuroBloc/MyoBloc since 1999 for treatment of cervical dystonia, hyperhidrosis, spastic conditions, cerebral palsy, hemifacial spasm, bladder dysfunction, spasmodic dysphonia, sialorrhoea, anal fissures, piriformis syndrome, various pain conditions and cosmetic applications.
D, Dressler, R, Eleopra
openaire   +2 more sources

Botulinum Toxin Type B for Dynamic Glabellar Rhytides Refractory to Botulinum Toxin Type A

Dermatologic Surgery, 2003
Botulinum toxin type B (BTX-B; Myobloc) has recently been introduced for the treatment of dynamic rhytides. This serotype is structurally similar to botulinum toxin type A (BTX-A; Botox) and appears to produce equivalent muscular paralysis. Because of the fact that some patients may become resistant to the effects of BTX-A with its continued use or may
Tina S, Alster, Jason R, Lupton
openaire   +2 more sources

Temporary autonomic modulation with botulinum toxin type A to reduce atrial fibrillation after cardiac surgery.

Heart Rhythm, 2019
BACKGROUND Postoperative atrial fibrillation (POAF) frequently complicates cardiac surgery and is associated with worse outcomes. The cardiac autonomic nervous system is implicated in the pathogenesis of POAF. OBJECTIVE The purpose of this study was to
N. Waldron   +12 more
semanticscholar   +1 more source

Botulinum Toxin Type B

Dermatologic Surgery, 2003
Botulinum toxin B is an antigenically distinct form of Botulinum toxin which has unique physical and clinical properties that distinguish it from Botulinum toxin A.To describe properties of Botulinum toxin B.More rapid onset, greater diffusion characteristics as well as diminished longevity have been identified to date in previous studies.BTX-B is safe
openaire   +2 more sources

Home - About - Disclaimer - Privacy